For nonseminoma, 5-year overall survival was 75.2%, 5-year progression-free survival was 68.6%; in the good prognosis group, the 5-year overall survival rate is 95%, 5-year progression-free survival rate is 85.7%; in the intermediate prognostic group, the 5-year overall survival rate is 57.1%, 5-year progression-free survival rate is 42.1%; in our study, there is no poor prognosis group for nonseminoma.